Francis P. Tally
Cubist Pharmaceuticals
17 Papers
111 Citations
Francis P. Tally is an academic researcher from Cubist Pharmaceuticals. The author has contributed to research in topics: Daptomycin & Antibiotics. The author has an hindex of 13, co-authored 17 publications.
Chat about Author
Papers
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Vance G. Fowler,Helen W. Boucher,G. Ralph Corey,Elias Abrutyn,Adolf W. Karchmer,Mark E. Rupp,Donald P. Levine,Henry F. Chambers,Francis P. Tally,Gloria Vigliani,Christopher H. Cabell,Arthur Stanley Link,Ignace DeMeyer,Scott G. Filler,Marcus J. Zervos,Paul P. Cook,Jeffrey Parsonnet,Jack M. Bernstein,Connie S. Price,Graeme N. Forrest,Gerd Fätkenheuer,Marcelo Gareca,Susan J. Rehm,Hans Reinhardt Brodt,Alan D. Tice,Sara E. Cosgrove +25 more
TL;DR: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
Robert D. Arbeit,Dennis G. Maki,Francis P. Tally,Edward Campanaro,Barry I. Eisenstein,Investigators +5 more
TL;DR: The safety and efficacy of daptomycin were comparable with conventional therapy, and the frequency and distribution of adverse events were similar among both treatment groups.
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
TL;DR: Daptomycin is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI) that has a unique mechanism of action that results in destruction of the membrane potential.
Patent
Methods for administration of antibiotics
Frederick B. Oleson,Francis P. Tally +1 more
- 24 Sep 1999
TL;DR: In this paper, the authors provide methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity, and also provide methods of administering quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.
36